Abiraterone (Zytiga): Mechanism of Zytiga
CYP17A1 inhibitor - Wikipedia
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. - Abstract - Europe PMC
PDF) CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
Abiraterone, CYP17 inhibitor Abiraterone (CB-7598)-Xcessbio Biosciences Inc
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1 | Drug Metabolism & Disposition
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Steroid synthesis pathway and aromatization. Abiraterone is a novel... | Download Scientific Diagram
CYP17A1 - an overview | ScienceDirect Topics
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
CYP17A1 - an overview | ScienceDirect Topics
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
CYP17 inhibitors for prostate cancer therapy. - Abstract - Europe PMC
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Steroid/androgen synthesis pathway and the sites of inhibition of... | Download Scientific Diagram
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
